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Components of the classical immune response mediate most
traditional acts of destructive inflammation in body tissues.
These events normally begin with the presentation of new
peptide antigens to helper T lymphocytes by antigen-presenting
cells residing within the lymphoid system. This engagement
results in the elaboration of new lymphokines, and/or the
emergence of new effector T cells and antibodies. These same
developmental processes and events are also thought to occur
when antigens are first recognized in the renal parenchyma. Not
all immunologic responses within the kidney, however, are
necessarily inflammatory.
The biology of somatic renal cells, for example, may only be
phenotypically altered after contact with the immune system,
and such contact may take place in the absence of any obvious
injury. The immune response, therefore, may sometimes
largely act as a signaling messenger for biologic change. Anti-
bodies or antigen-binding soluble factors mediating these bio-
logic changes would be specifically targeted, theoretically, to
ligands expressed on certain cell types. These immune media-
tors are highly focused in their interaction and, depending on
the second messenger signals, would produce phenotypic alter-
ations in the target cell which are either protective or detrimen-
tal to the host. Some of the mechanisms whereby the immune
system can engage and biologically alter renal somatic cells are
the focus of the following review.
Antigen-binding T cell proteins
The characterization of soluble antigen-binding proteins or
T-helper factors (ThF) provides a predictable mechanism for
the induction of effector T cell responses in the absence of
cell-to-cell contact. Such factors are mature, soluble end-
products which can functionally substitute for their respective
parent lymphocytes [1, 2]. They are produced by T cells, are
usually antigen-specific, and traditionally engage the effector
limb of an immune response [3—8]. Both T and B cell differen-
tiation may be enhanced by such factors [9]. In contrast,
antigen-binding suppressor proteins may do the opposite [9—12].
Previous biochemical characterizations of various helper fac-
tors have established that these molecules are commonly com-
posed of two chains. One chain functions as an antigen-binding
domain while the other expresses class II MHC determinants,
thereby providing immunologic restriction [2, 3, 7, 9, 13—16].
At least one ThF has been described in experimental inter-
stitial nephritis [2]. This factor induces the nephritogenic cell-
mediated effector response in anti-tubular basement membrane
(aTBM) disease, demonstrates fine antigenic specificity, and is
composed of two molecular chains [2, 16]. The ThF is derived
from specific CD4 T-helper cells reactive to 3M-i antigen, the
30,000 Mr glycoprotein autoantigen of aTBM disease [17].
In this experimental model, genetically susceptible SJL mice
(H2s, IgH-th) develop tubulointerstitial nephritis after immuni-
zation with renal tubular antigen in complete Freund's adjuvant
[18—29]. The 3M-i target antigen is synthesized by proximal
tubular cells (MCT) and in vivo is later distributed along cortical
tubular basement membranes [17, 19, 20, 21]. CD4 T helper
cells that are both 3M-i antigen-specific and I-A restricted
induce the appearance of CD8 nephritogenic effector cells and
polyclonal anti-3M-i antibodies [18, 22, 23, 26—30].
ThF is secreted by the CD4 helper cell and can be isolated
as the non-covalently bound chains of a heterodimeric mole-
cule. One chain binds 3M-i and this antigen-binding chain
expresses components of the T cell receptor (TcR) as evidenced
by its ligation by several anti-T cell receptor-like antibodies [2].
Monoclonal antibody 14-30 also binds the framework region of
the ThF at a determinant common to other antigen-binding
factors, while another monoclonal antibody aM3O recognizes a
portion of the a:f heterodmieric TcR [27]. Other antibodies
which bind to this chain include KJ23, an antibody specific for
Vf3i7, and an anti-idiotypic antibody raised against antibodies
eluted from nephntis mice [31]. KJ23 recognizes a domain
shared by the 3M-i idiotypic network which includes a soluble
T cell suppressor factor, and effector cells [32—33]. The second
chain of the ThF dimer (Mr —82,000) expresses A)3 determi-
nants, the munne equivalents of human class II MHC mole-
cules, and binds to an antiAI3s monoclonal antibody.
ThF performs two known functions, the first is immunologi-
cal and the second is biological. In the first, ThF promotes a
dose-dependent induction of CD8 effector cells, in the pres-
ence of IL-2 and 3M-I [2]. Notably, the immunologic helper
function of ThF is not perturbed even after physical disruption
of its component chains through chemical alterations of alkyla-
tion and reduction [2]. The second and more novel function of
this antigen-binding protein is its ability to selectively alter
molecular and cellular events within proximal tubular cells.
MCT cells in culture, as an example, secrete several colla-
gens into their supernatants, including collagen types I, III and
IV [34, 35]. Culture of these cells with various concentrations of
ThF leads to differential effects on the secretion of types I and
IV collagen into the supernatants [36]. After 72 hours of culture,
a 20-fold dose-dependent decrement in type IV collagen secre-
tion can be observed. In contrast, the secretion of type I
collagen is either unchanged or slightly enhanced by ThF [36].
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The decrement in type IV collagen secretion strikingly con-
trasts the increases seen after the incubation of MCT cells with
other cytokines and cytokine-like paracrine modulators, includ-
ing TGF/3, EGF and other antigen-specific T cell helper factors
[2, 26].
The mechanism by which ThF down-regulates type IV col-
lagen secretion is partially understood. In vitro experiments
measuring the relative abundance of transcripts encoding col-
lagen chains aI(IV) and a2(I) in MCT cells after stimulation
with ThF revealed a threefold reduction in mRNA encoding the
aI(IV) chain [36]. By contrast, a slight elevation in the number
of transcripts occurs with type I collagen. In vitro nuclear
run-off studies demonstrate that the principal reason for the
reduction in levels of mRNA encoding type IV collagen can be
attributed to an overall decrease in its rate of transcription. In
renal tissues of mice with early aTBM disease, T cells that stain
for 3M-I antigen-reactive ThF are found within the interstitial
spaces. In situ hybridization studies of such nephritic kidneys
also demonstrate a parallel reduction in transcripts encoding
type IV collagen [36]. This decrease in transcripts is reflected in
lower amounts of type IV collagen in basement membrane as
interstitial injury progresses.
The primary constituents of tubular basement membrane are
type IV collagen and laminin. The renal tubular epithelium sits
on this laminar support, suspended by a fibrillar collagen
scaffolding that partitions the compartments of the tubulointer-
stitium [37—39]. One consequence of releasing antigen-binding
proteins like ThF into the interstitium is a substantial decrease
in type IV ctllagen. Alterations in the cellular expression of
extracellular matrix collagens by ThF-like moieties can directly
facilitate the deformative remodeling of the tubulointerstitium
during interstitial inflammation, and may provide an immuno-
logic basis for the process of tubular atrophy and fibrogenesis
[34, 36, 40, 41].
Antibody against renal cells
Antibodies to Heymann nephritis antigen complex
A paradigm for the modulating influence of antibody against
antigen on glomerular epithelial cells (GEC) is Heymann ne-
phritis, an experimental model of membranous nephropathy
[42]. In the active form of disease, immunization of rats with
whole kidney homogenates in adjuvant produces a heavy
proteinuria. In the passive form, proteinuria is induced by the
injection of either autologous or heterologous antibodies or
F(Ab)'2 fragments that recognize a cellular antigen called Fx1A/
HNAC/gp330, currently referred to as the Heymann nephritis
antigen complex (HNAC) [personal communication, Dr. M.G.
Farquhar; 43—47]. In both the active and passive forms of the
disease, subepithelial immune deposits form along the subepi-
thelial aspects of the GBM [46—50]. The interaction of antibody
with HNAC in the tuft is not directly injurious to the GBM,
since proteinuria occurs only after local complement activation;
however, administration of passively transferred antibodies
against brush border antigens can invoke changes along the
proximal tubule in the absence of complement activation [51].
More recently, it has been observed that the antigen complex
recognized by anti-liNAC antibodies (aHNAC-Ab) are likely
subunits of a large, 400 to 600,000 Mr multimeric membrane-
associated glycoprotein (HNAC) that is found with restricted
polarity on the brush border of proximal tubular cells in the
clathrin-rich inter-microvillar domain of the cell membrane and
in the glomerular epithelium at the soles of the foot processes
where the cell membrane faces the GBM [52—58].
Immunohistochemical localization of HNAC to the glomeru-
lar epithelial cell (GEC) has caused a reappraisal of the patho-
genic mechanism of this disorder. Originally, it had been
presumed that circulating immune complex formation occurred
after circulating aHNAC-Ab became bound to small amounts of
tubular brush border antigen that had spontaneously leaked
from the kidney and entered the serum [43]. These complexes
would deposit within the GBM in a subepithelial distribution
and initiated disease. Currently, however, it is believed that the
formation of immune deposits occurs largely in situ [37, 50, 59].
aHNAC-Ab somehow traverse the GBM and then bind avidly
to HNAC in the clathrin-coated pits at the base of podocytes
and subsequently form immune deposits [60—63]. The associa-
tion of HNAC with clathrin, its partial similarity to brushin [58],
and its homology to the LDL receptor suggests that the true
nature of the complex, multimeric molecule is still uncertain
[58, 64, 65]. The association of antibody with HNAC is highly
specific, however, and certain epitopes are cDable of inciting
greater nephritogenic responses than others. For example,
polyclonal brush border antibody preparations with high reac-
tivity for HNAC produce greater proteinuria than isolated
monospecific fractions [60, 66, 67]. Within these heterogeneous
preparations, gp330-specific antibodies have been shown
to be the most nephritogenic [58]. Cell-surface binding of
aHNAC-Ab serves as the nidus for the subsequent develop-
ment of subepithelial immune complexes which are shed into
the lamina rarae externae and subsequently stabilized by
crosslinking [47]. Aggregation of immune complexes leads to
formation of large immune deposits which take form within 15
minutes and may persist in the GBM for up to eight days [47].
In culture, clustering and shedding of immune deposits occurs
preferentially in the presence of polyclonal immune serum,
rather than monoclonal serum, indicating that binding of mul-
tiple epitopes may occur. This arrangement likely optimizes
lattice formation for the ensuing complement activation which
occurs in Heymann nephritis [60, 67—69]. The enlargement of
immune deposits is dependent on the continued biosynthesis of
gp330 which is transported from the endoplasmic reticulum and
Golgi apparatus to sites of immune interaction near the clathrin-
coated pits [58]. Persistence of the immune deposits in the
lamina rara externa of the GBM may occur because of ongoing
exposure of nephritogenic epitopes to aHNAC-Ab within the
immune complexes. Furthermore, the association of gp330 with
clathrin is so strong that it is maintained even after isolation of
brush border membranes by biochemical fractionation [58, 61].
With persistence of immune deposition in Heymann nephri-
tis, significant thickening of the GBM proceeds [70]. Progres-
sive thickening follows remodeling of the GBM structure itself
[71—74]. However, the remodeling process is unusual in that
there is no obvious increase in the synthesis in type IV collagen,
laminin, or fibronectin [70]. Measurement of mRNA levels for
these matrix components does not increase when measured
from isolated glomeruli at either one week, three weeks, or
three months [70]. Whether there is an increase in some other
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undefined structural matrix constituent is not known. Candi-
dates for such a component would include entactin and proteo-
glycans. Alternatively, a volumetric increase in the GBM may
have taken place without concomitant new matrix synthesis,
namely, the density of the membrane becomes decreased [70].
The nephritogenicity of HNAC may depend, in part, on
expression of conformational epitopes not normally visible in
vivo. After ligation by polyclonal antibodies, but not mono-
clonal antibodies, HNAC undergoes antigenic modulation [47,
48]. HNAC is subsequently redistributed on the apical mem-
brane surface, patched, actively capped, and temporarily inter-
nalized after initial cross linking [47, 48]. These processes are
influenced by cytoskeletal components and may be linked to
one another, affecting the differential expression of epitopic
specificity.
The cytoskeleton of a cell supports and provides its infra-
structure. It operates dynamically and responsively to the
microenvironment, in conjunction with a cell's molecular mo-
tors. As an example, the cytoskeleton behaves relatively pas-
sively when monovalent Fab' fragments of aHNAC-AB bind to
Heymann nephritis antigens on the cell surface [45]. However,
after binding of aHNAC-Ab and crosslinking of HNAC, the
cytoskeleton becomes engaged in new actions. HNAC is redis-
tributed and bound by aHNAC-Ab that form aggregates or
"caps." These subsequently redistribute within the cell mem-
brane [60, 75]. This capping phenomenon, which is an active
process dependent on the presence of divalent cations, can be
precluded by pretreatment of GEC with cytochalasin B which
disrupts microfilaments, or by the addition of a calcium iono-
phore [75, 76]. Like capping, antigenic redistribution is also
sensitive to the administration of colchicine which disrupts
microtubular structures [77]. After cross linking of HNAC by
aHNAC-Ab, these antigen-antibody complexes subsequently
disappear from the cell membrane of the podocyte. Their
subsequent reappearance in the subepithelial space at sites of
slit diaphragms implies some sort of translocation to this region
[47, 48].
Using differential extraction techniques, it has been shown
that a conversion of HNAC from the stage of a detergent-
soluble, membrane-associated form to an insoluble cytoskele-
ton-bound one occurs in the presence of aHNAC-Ab [76]. In
the latter conformation, HNAC is tightly associated with mi-
crofilaments, thereby gaining mobility within the cytoplasm.
Although the exact role of the association of the cytoskeleton
with HNAC is not defined by these observations, it is likely that
its role is fundamental to further antigen processing, since the
administration of chlorpromazine in vitro and in vivo com-
pletely abrogates the development of Heymann nephritis [75].
Chlorpromazine inhibits the actions of calmodulin and protein
kinase C and mediates a decrease in the fluid nature of the cell
membrane through its effects on microfilaments [75].
The induction of proteinuria by monoclonal aHNAC-Ab is
rapid, reversible and transient. This interaction is specific and
does not proceed when a monoclonal antibody directed against
a smaller 70,000 Mr subunit of the 600,000 Mr multimer is
substituted for polyclonal aHNAC-Ab [55]. This latter antibody
may interact synergistically with HNAC by increasing the
permeability of the endothelium, thereby permitting a greater
quantity of aHNAC-Ab to traverse the GBM, gaining access to
the surface of GEC [60]. Furthermore, polyclonal aHNAC-Ab
is not uniquely nephritogenic in Heymann nephritis; a distinct
antibody directed against the 108,000 Mr subunit of the 600,000
Mr multimer seems to elicit an even more severe nephritogenic
response than polyclonal aHNAC-Ab [77]. Unfortunately, the
molecular mechanism which governs the alteration of glomer-
ular permeability in Heymann nephritis remains uncertain.
Interestingly, recent data also suggest a role for aHNAC-Ab
in the alteration of cell adhesion of proximal tubular epithelium
to the extracellular matrix. Proximal tubular epithelium in
primary culture attach to their substratum and propagate as a
differentiated structure [78]. These effects are mediated, in part,
by HNAC. The detergent-solubilized HNAC fraction of freshly
isolated epithelium has specific affinity for extracellular matrix
components, including type I collagen, laminin and fibronectin,
which is reminiscent of cell receptor /31 integrins [79—81].
However, the affinity for these matrix components is neither
blocked by the tripeptide sequence, RGD (arginine-glycine-
asparagine), nor by synthetic fibronectin peptides, implying a
non-integrin binding mechanism for HNAC. This is not unex-
pected since the distribution of HNAC on glomerular epithe-
hum differs from that of the /31 integrins. The inhibition of
attachment of this epithelium to these matrix constituents in
vitro by aHNAC-Ab strongly contends that a receptor epitope
of HNAC mediates part of this adhesion [78]. Furthermore, the
inhibition is not secondary to a toxic effect since the epithehial
attachment to these matrix components is fully restored after
removal of antibody from the cell surface. Another immunobi-
ological effect of aHNAC-Ab is the prevention of the expected
increase in thymidine incorporation by tubular epithelium after
their culture on extracellular matrices [781.
A disturbance of proximal tubular endocytosis in rats is also
mediated by aHNAC-Ab. After the injection of heterologous
HNAC, there is a pronounced diminution in the endocytic
uptake of FITC-conjugated dextran and horseradish peroxidase
[82]. Loss of microvillar structures and flattening of the epithe-
hal cells occurs [58]. Immunocytochemical analysis discloses a
coincident and parallel reduction in the amount of several apical
surface antigens, including HNAC, clathrin and an ATP-depen-
dent proton pump. Clathrin and antigen-antibody complexes
can be found in the tubular lumen. Since clathrin-coated pits
play a major role in the endocytosis of filtered proteins in
proximal tubules, it is not improbable that the latter phenome-
non contributes to the tubular dysfunction which attends Hey-
mann nephritis.
Antibodies to other glomerular epithelial antigens
Several other experimental models may also provide insight
into potential signaling mechanisms using immunoglobuhin rec-
ognition of glomerular epithelial cells. In one model in rats, a
single intravenous injection of the monoclonal antibody 5-1-6
(a5-1-6) predictably produces an immediate massive proteinuria
in a dose-dependent fashion [83]. The inciting antigen has been
localized exclusively to rat kidney and defines the organ spec-
ificity of this interaction. Protein excretion peaks after eight
days and then gradually declines. Immunoperoxidase studies
demonstrate a linear binding pattern along glomerular capillary
walls within two hours after injection of aS-1-6. By the third
day, this pattern is succeeded by a fine granular pattern of
fluorescence whose intensity diminishes by twelve days. This
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change in immunofluorescence implies mobility of the autoan-
tigen and quite plausibly, molecular rearrangement of immune
complexes. Correlative ultrastructural studies have noted anti-
body within multivesicular bodies and localization to the sur-
face of foot processes at slit diaphragms, similar to HNAC. The
intracellular presence of antibody contrasts the mechanism of
induction of Heymann nephritis where much of the antibody is
seemingly not internalized. Histologically, there is partial re-
traction of epithelial foot processes. Taken collectively, these
data imply that the determinants recognized by a5-i-6 directly
participate in the maintenance of the permselective function of
the glomerular capillary walls. Moreover, the structural alter-
ations therein might initiate or augment the mechanism(s)
causing proteinuria. The lesions produced by a5-i-6 recapitu-
late the histopathological findings attendant in other experimen-
tal models of non-inflammatory glomerulonephritis to include
nephrosis induced by adriamycin, systemic protein overload
and by the aminonucleoside puromycin [84—91].
In the K9/9 nephritis model, even more impressive structural
alterations in GEC appear after the administration of this
monoclonal IgG antibody. This immunoglobulin recognizes a
specific sialoglycoprotein in Lewis rat kidney which leads to
rapid and reversible proteinuric response. K9/9 immunoprecip-
itates both a 115 kD sialoglycoprotein of the glomerular cell
membrane and a 107,000 Mr membrane component from prox-
imal tubules [92]. Leukocytes and complement are not involved
in the mechanism of proteinuria; however, there is an absolute
requirement of the nonselective activation of the immune
system by adjuvant for expression of the response. The struc-
tural alterations which appear include microvillous transforma-
tion, effacement of foot processes, vacuolar transformation and
epithelial cell detachment from the GBM [92]. This model
defines a specific nephritogenic epitope since antibodies which
bind to spatially close but different epitopes cannot elicit a
similar nephritogenic response [93].
In both of these models, it appears that immune recognition
of epithelial ligands interferes with the orderly contact and
interface of structural elements which comprise normal tissue
planes. Antibody engagement subsequently disrupts the func-
tional activity of these elements in their support of the microen-
vironment.
Antibodies to proximal tubular cells
Antibodies to determinants expressed by proximal tubular
cells can also have an effect on MHC class II expression [94]. In
aTBM disease, for example, susceptible strains of SJL mice
(H2s, IgH-ib) develop both class I-restricted CD8 and class
Il-restricted CD4 effector cells early in disease [17, 22, 23, 26,
28—30]. Within several days, however, class I-restricted effector
cells emerge as the predominant phenotype, and adoptive
transfer of these particular effectors will produce disease [24].
By contrast, the non-susceptible strain of BlO.A (H2a,
IgH-ib) mice develops a class lI-restricted CD4 effector cell
response [24]. Although this effector cell phenotype recognizes
3M-i in delayed-type hypersensitivity assays, it is normally not
nephritogenic. Such class TI-restricted cells, however, can
mediate tubulointerstitial inflammation upon adoptive transfer
into syngeneic recipients whose tubular epithelium have been
primed by an appropriate cytokine. For example, pretreatment
of Bi0.A mice with ryIFN augments the expression of class II
antigens on proximal tubular epithelium, rendering this strain
susceptible to interstitial nephritis [94]. Prior to such treatment,
class II antigens are present in insufficient quantities on 3M-l-
secreting tubular cells to mediate the T cell recognition of 3M-i.
This is not surprising, since the normal expression of class II by
proximal tubular cells is minimal [94-96]. However, under
appropriate conditions, tubular epithelium can present antigen
[25, 94—97], and we believe that ryIFN permissively increases
the immunologic visibility of 3M-i, thus enhancing its intrinsic
antigen-presenting capacity.
It appears that the permissive effect of ryIFN can be abro-
gated by the passive transfer of antibodies to 3M-i [94]. Bi0.A
mice pretreated with a3M-1-Ab and ryIFN 48 hours before
receipt of effector CD4 cells prevented induction of a nephri-
togenic response [94]. Protection was afforded by a3M-l-Ab
even when administered as late as 24 hours before adoptive
transfer. Immunofluorescent staining of class II molecules on
the tubules from B i0.A mice was minimal in comparison to
mice which were exposed to an irrelevant control antibody,
where the latter stained abundantly for class II. Additional
studies suggested that the protective effect of a3M-l-Ab was
not simply due to the interference of T cell recognition of
antigen, since a3M-1-Ab could not provide a protective re-
sponse in syngeneic recipients of adoptively transferred 3M-i-
reactive, CD8 effector cells.
Kidneys from recipients of passively transferred a3M-i-Ab
also stain TBM with increased intensity when overlain with
additional a3M-i-Ab at the time of immunofluorescent analysis.
Taken together, these data suggest that passively transferred
a3M-l-Ab neither completely blocked T cell epitope recogni-
tion, nor influenced the expression of class I determinants [94].
Further studies have examined the mechanism by which
a3M-i-Ab down-regulates class II. These investigations reveal
a diminution in levels of mRNA transcripts for class II deter-
minants in MCT cells incubated with a3M-1-Ab for 24 hours.
Similar effects were obtained when polycional IgG eluates from
kidneys of susceptible Bi0.S and non-susceptible BiO.A strains
were incubated with MCT cells. Kidney-bound a3M-i-Ab from
either strain down-regulated the transcript levels for class II
antigens. Unexpectedly, however, exposure of MCT cells to
the haplotype specific anti-class I antibody aKs nearly tripled
class II mRNA levels [94].
Nuclear run-off transcription assays performed on MCT cells
cultured in the presence of a3M-1-Ab pinpoint the modulatory
effect of a3M-i-Ab to an inhibition of class II gene activation
[94]. A 50% decrease in the rate of class II mRNA transcription
was observed with a3M-l-Ab in comparison to levels obtained
from cells incubated with control antibody. There was no effect
on class I transcription. In situ hybridization studies of kidneys
of mice immunized to produce aTBM disease corroborated the
in vitro findings. At two or five weeks, the period during which
a3M-1-Ab are first deposited along the tubular basement mem-
brane and before there is a strong mononuclear reaction,
one-sixth to one-third of the mRNA levels of class II MHC are
expressed by mice immunized to produce disease in compari-
son to controls [94]. Furthermore, the tubules from mice with
cmTBM disease demonstrate a much heavier deposition of en-
dogenous a3M-i-Ab than those from controls.
In summary, a3M-i-Ab binding to proximal tubular cell
surface 3M-i selectively down-regulates the expression of class
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II MHC determinants by repressing transcription. The func-
tional and biological effects result in a diminution of cell surface
class II expression that attenuate CD4-mediated T cell re-
sponses. Presumably the lack of a response is the result of a
failure in antigen presentation by the proximal tubular epithe-
hum,
Summary
The various theories discussed here suggest that somatic
renal cells are susceptible to biologic modulation by the immune
system independent of an inflammatory effect. (I) The mode of
repression of type IV collagen synthesis by novel, soluble
antigen-binding proteins, the down-regulation of class II MHC
expression with interruption of antigen presentation to epithelia
after selective gene regulation by antibody, and the diverse
interactions of antibody with renal glomerular cells producing
functional disturbances in endocytosis and permselectivity; (2)
modification of surface-antigen composition; (3) alteration of
matrix deposition, remodeling and composition; (4) biophysical
perturbation of cytoskeletal and cell membrane components; (5)
and lastly, alterations in cell adhesion through cell-surface
alterations, all lend testimony to the richness of the signal
transduction pathways in somatic cells. Although the preceding
examples represent only a small fraction of those which may
take place within the glomerular and tubular microenviron-
ments, these paradigms may nevertheless serve as new models
upon which one can consider the multitude of potential com-
munications between disparate biologic systems that connect in
complex organisms.
Reprint requests to Eric G. Neilson, M.D., Renal-Electrolyte Divi-
sion, 700 Clinical Research Building, University of Pennsylvania, 422
Curie Boulevard, Philadelphia, Pennsylvania 19104-6144, USA.
References
1. WEBB DR, KAPP JA, PIERCE CW: The biochemistry of antigen-
specific T-cell factors. Ann Rev Immunol 1:423—438, 1983
2. HINES WH, MANN RA, KELLY CJ, NEILSON EG: Biochemical and
functional characterization of an antigen-specific helper T cell
factor which induces the effector T cell repertoire in autoimmune
interstitial nephritis. J Immunol 144:75—83, 1990
3. APTE RN, ESHIIAR Z, Low I, ZINGER H, MOZES E: Charactens-
tics of a poly(LTyr,LGlu)-poly(DLAIa)-poly(LLys)-specific helper
factor derived from a T cell hybridoma. Eur J Immunol 11:931—936,
1981
4. VANDEBRIEL RJ, DE WEGER RA, Los G, LOVEREN HV, WIEGERS
GJ, OUDE WEERNINK PA, DEN OTTER W: Two specific T cell
factors that initiate immune responses in murine allograft systems.
J Immunol 143:66—73, 1989
5. DEANS JP, KROWKA JF, MOSMANN T, PILARSKI LM: Antigen-
specific helper factor reacts with antibody to the T-cell receptor. J
Immunol 14:103—107, 1987
6. ZHENG H, BOYER M, FOTEDAR A, SINGH B, GREENE DR: An
antigen-specific helper T cell hybridoma produces an antigen-
specific suppressor inducer molecule with identical antigenic fine
specificity. Implications for the antigen recognition and function of
helper and suppressor inducer T cells. J Immunol 140:1351—1358,
1989
7. ZHENG H, SAHAI BM, KILGANNON P, FOTEDAR A, GREEN DR:
Specific inhibition of cell-surface T-cell receptor expression by
antisense oligodeoxynucleotides and its specific effect on the pro-
duction of an antigen-specific regulatory T-cell factor. Proc NatI
Acad Sci USA 86:3758—3762, 1989
8. KWONG PC, TEH HS: Characterization of a Dd-specific helper
factor required for the induction of cytotoxic responses to alloan-
tigens with the use of monoclonal antibodies specific for the helper
factor of the T-cell antigen receptor. Immunology 61:143—150, 1987
9. DEANS JP, KR0WKA iF, MOSMANN T, PILARSKI LM: Antigen-
specific helper factor reacts with antibody to the T-cell receptor. J
Immunogen 14:103—107, 1987
10. NEILSON EG, KELLY CJ, CLAYMAN MD, HINES WH, HAVERTY T,
SUN MJ, BLANCHARD N: Murine interstitial nephritis. VII. Sup-
pression of renal injury following treatment with a soluble suppres-
sor factor, TsFl. J Immunol 139:1518—1524, 1987
11. KELLY CJ, CLAYMAN MD, HINES WH, NEIL50N EG: Therapeutic
immune regulation in experimental interstitial nephritis with sup-
pressor T cells and their soluble factors. Ciba Foundation Sympo-
sium 129:73—87, 1987
12. FERGUSON TA, IVERSON GM: Isolation and characterization of an
antigen-specific suppressor inducer molecule from serum of hyper-
immune mice by using a monoclonal antibody. J Immunol 136:
2896—2903, 1986
13. FAIRCHILD RL, KUBO RT, MOORHEAD JW: Soluble factors in
tolerance and contact sensitivity to 2,4-dinitro-fluorobenzene in
mice, IX. A monoclonal T cell suppressor molecule is structurally
and serologically related to the a//3 T cell receptor. J Immunol
141:3342—3348, 1989
14. Gu R, ULLRICH SJ, Foo-PHILLIps M, HATHCOCK KS, APPELLA
E, HODES RI: Antigen-specific helper function of cell-free T cell
products bearing TCR Vf38 determinants, Science 244:1477—1479,
1989
15. YAMAUCHI K, CHAO D, MuaPHY DB, GERSHON RK: Molecular
composition of an antigen-specific, Ly-l T suppressor inducer
factor: One molecule binds antigen and is I-J—; another is I-J+,
does not bind antigen, and imparts an Igh-variable region linked
restriction, J Exp Med 126:423-428, 1982
16. IwATA M, ADACHI M, IsHIzAKA K: Antigen-specific T cells that
form IgE-potentiating factor, IgG-potentiating factor, and antigen-
specific glycosylation enhancing factor on antigenic stimulation. J
Immunol 140:2534—2542, 1988
17. CLAYMAN MD, MICHAUD L, BRENTJENS J, ANDRES GA, KEFAL-
IDES NA, NEILSON EU: Isolation of the target antigen of human
anti-tubular basement membrane antibody-associated interstitial
nephritis. J Clin Invest 77:1143—1 147, 1986
18. MANN R, KELLY Ci, HINES WH, CLAYMAN MD, BLANCHARD N,
SUN Mi, NEILSON EG: Effector T cell differentiation in experimen-
tal interstitial nephntis. I. The development and modulation of
effector lymphocyte maturation by I-J regulatory cells. Jlmmunol
136:4200—4208, 1987
19. CLAYMAN MD, MARTINEZ-HERNANDEZ A, MICHAUD L, ALPER R,
MANN R, KEFALIDES NA, NEILSON EG: Isolation and character-
ization of the nephritogenic antigen producing anti-tubular base-
ment membrane disease. J Exp Med 161:290—305, 1985
20. NEILS0N EG, SUN MJ, KELLY Ci, HINES WH, HAVERTY TP,
CLAYMAN MD, COOKE NE: Molecular characterization of a major
nephritogenic domain in the autoantigen of anti-tubular basement
membrane disease. Proc Natl Acad Sci USA 88:2006—2010, 1991
21. HAvERTY TP, KELLY CJ, HINES WH, AMENTA PS, WATANABE M,
HARPER RA, KEFALIDES NA, NEILSON EG: Characterization of a
renal tubular epithehial cell line which secretes the autologous target
antigen of autoimmune interstitial nephritis. J Cell Biol 107:1359—
1368, 1988
22. HINES WH, MANN RA, KELLY CJ, NEILSON EG: Murine intersti-
tial nephritis: IX. Induction of the nephntogenic effector T cell
repertoire with an antigen-specific T cell cytokine. J Immunol
144:75—83, 1990
23. NEILSON EU, PHILLIPS SM: Murine interstitial nephritis. I. Anal-
ysis of disease susceptibility and its relationship to pleiomorphic
gene products defining both immune response genes and a restric-
tive requirement for cytotoxic T cells at H-2K. J Exp Med 155:
1075—1085, 1982
24. ZAKHEIM B, MCCAFFERTY E, PHILLIPS SM, CLAYMAN M, NEIL-
SON EG: Murine interstitial nephritis. II. The adoptive transfer of
disease with immune T lymphocytes produces a phenotypically
complex interstitial lesion. J Immunol 133:234—239, 1984
25. KELLY Ci, ROTH DA, MEYERS CM: Immune recognition and
response to the renal interstitium. Kidney Int 31:518—530, 1991
26. CLAYMAN MD, MICHAUD L, NEILSON EG: Murine interstitial
Yee and Neilson: Immune system mechanisms 133
nephritis. VI. Characterization of the B cell response in anti-tubular
basement membrane disease. J Immunol 134:2375—2382, 1987
27. MEYERS CM, KELLY CJ: Effector mechanisms in organ-specific
autoimmunity. J C/in Invest 88:408—415, 1991
28. MANN R, ZAKHEIM B, CLAYMAN M, MCCAFFERTY E, MICHAUD
E, NEILSON EG: Murine interstitial nephritis. IV. Long-term cul-
tured L3T4 T cell lines transfer delayed expression of disease as
I-A restricted inducers of the effector T cell repertoire. J Immunol
135:286—293, 1985
29. MANN R, NEILSON EG: The autoinduction of antigen specific Lyt
2 suppressor T cells diminishes the expression of interstitial
nephritis in mice with antitubular basement membrane disease. J
Immuno/ 136:908—912, 1986
30. NEILSON EG, MCCAFFERTY E, MANN R, MICHAUD L, CLAYMAN
M: Murine interstitial nephritis. III The selection of phenotypic
(Lyt and L3T4) and idiotypic(RE-Id) T cell preferences by genes in
Igh-1 and H-2K characterize the cell-mediated potential for disease
expression: Susceptible mice provide a unique effector T cell
repertoire in response to tubular antigen. J Immunol 139:2242—
2249, 1985
31. KAPPLER J, WADE T, WHITE J, KUSHNIR E, BLACKMAN M, BILL
J, ROEHM N, MARRACK P: A T cell receptor V/3 segment that
imparts reactivity to a class LI major histocompatibility product.
Cell 49:263—271, 1987
32. NEILSON EG, ZAKHEIM B: T cell regulation, anti-idiotypic immu-
nity, and the nephntogenic immune response. Kidney mt 24:289—
302, 1983
33. CLAYMAN MD, SUN MJ, MICHAUD L, BRILL-DA5HOFF J, RIBLET
R, NEILSON EG: Clonotypic heterogeneity in experimental nephri-
tis. Restricted specificity of the anti-tubular basement membrane B
cell repertoire is associated with a disease-modifying crossreactive
idiotype. J Exp Med 167:1296-13 12, 1988
34. KuCio OS, NEILSON EG, HAVERTY TP: Mechanisms of tubu-
lointerstitial fibrosis. Kidney mt 39:550—556, 1991
35. NEILSON EG, JIMENEZ SA, PHILLIPS SM: Cell mediated immunity
in interstitial nephritis. III. T lymphocyte mediated fibroblast
proliferation and collagen synthesis: An immune mechanism for
renal fibrogenesis. J Immunol 125:1708-1714, 1980
36. HAVERTY TP, KELLY CJ, HOYER JR, ALVAREZ R, NEILSON EG:
Tubular antigen-binding proteins repress transcription of type IV
collagen in the autoimmune target epithelium of experimental
interstitial nephritis. J C/in Invest 89:517—523, 1992
37. KARKEVELAS 0, KEFALIDES NA, AMENTA PS, MARTINEZ-HER-
NANDEZ A: Comparative ultrastructural localization of collagens
types III, IV, V and laminin in rat uterus and kidney. J Ultrastruct
MoiStructRes 100:137—155, 1988
38. TIMPL R, DZIADEK M: Structure, development, and molecular
pathology of basement membranes. Int Rev Exp Path 29:1—112,
1986
39. TIMPL R, AUMAILLEY M: Biochemistry of basement membranes.
Adv Nephrol 18:59—76, 1989
40. HEPTINSTALL RH: Pathology of end-stage kidney disease. Am J
Med 244:656—662, 1968
41. CARLSON EC: Morphology of isolated renal tubular and glomerular
basement membranes, in Renal Basement Membranes in Health
and Disease, edited by PRICE RG, HUDSON BG, Orlando, Aca-
demic Press, 1987, pp. 99—114
42. HEYMANN W, HACKEL DB, HARWOOD 5, WILSON SGF, HUNTER
JLP: Production of nephrotic syndrome in rats by Freund's adju-
vant and rat kidney suspensions. Proc Soc Exp Biol Med 100:660—
664, 1959
43. EDGINGTON TS, GLASSOCK RJ, WATSON JJ, DIXON FJ: Character-
ization and isolation of specific renal tubular antigens. J Immuno/
99:1199—1210, 1967
44. GLASsOCK RJ, EDGINGTON TS, WATSON JI, DIXON FJ: Autologous
immune complex nephritis induced with renal tubular antigen. II.
The pathogenetic mechanism. J Exp Med 127:573—588, 1968
45. SALANT DJ, MADAIO MP, ADLER S, STILMANT MM, COUSER WG:
Altered glomerular permeability induced by F(ab')2 and Fab' anti-
bodies to rat renal tubular epithelial antigen. Kidney mt 21:36-43,
1981
46. FEENSTRA K, VAN DEN LEE R, GREGEN HA, ARENDS A, HOEDE-
MAEKER P: Experimental glomerulonephritis in the rat induced by
antibodies directed against tubular antigens. I. The natural history:
A histologic and immunohistologic study at the light and the
ultrastructural level. Lab Invest 32:235—242, 1975
47. KERJASCHKI D, FARQUHAR MG: Immunocytochemical localization
of the heymann nephntis antigen (gp330) in glomerular epithelial
cells of normal Lewis rats. J Exp Med 157:667—686, 1983
48. KERJASCHKI D, MIETTJNEN A, FARQUHAR MG: Initial events in the
formation of immune deposits in passive Heymann nephritis:
gp330-anti-gp330 immune deposits form in epithelial coated pits and
rapidly become attached to the GBM. J Exp Med 166:109-128, 1987
49. BARABAS AZ, LANNIGAN R: Induction of an autologous immune-
complex glomerulonephritis in the rat induced by intravenous
injection of heterologous anti-rat kidney tubular antibody. Br J Exp
Pathol 55:47—55, 1974
50. VAN DAMME JC, FLEUREN GJ, BAKKER WW, VERNIER RL,
HOEDEMAEKER PJ: Experimental glomerulonephritis in the rat
induced by antibodies directed against tubular antigens. V. Fixed
glomerular antigens in the pathogenesis of heterologous immune
complex glomerulonephritis. Lab Invest 38:502—510, 1978
51. NOBLE B, ANDRES GA, BRENTJEN5 JR: Passively transferred
anti-brush border antibodies induce injury of proximal tubules in
the absence of complement. C/in Exp Immuno/ 56:281—288, 1983
52. KERJASCHKI D, FARQUHAR MG: The pathogenic glycoprotein of
Heymann nephritis is a membrane glycoprotein of the renal prox-
imal tubule brush border. Proc NatI Acad Sci USA 79:5557—5561,
1982
53. Mwrrit A, DEKAN 0, FARQUHAR MG: Monoclonal antibodies
against membrane proteins of the rat glomerulus. Am J Patho/
137:929—944, 1990
54. NATORI Y, HAYAKAWA I, SHIBATA S: Passive Heymann nephritis
with acute and severe proteinuria induced by heterologous anti-
body against renal tubular brush border glycoprotein gplo8. Lab
Invest 55:63—70, 1986
55. KERJASCHKI D, NORONHA-BLOB L, SACKTOR B, FARQUHAR MG:
Microdomains of distinctive glycoprotein composition in the kidney
proximal tubule brush border. J Cell Biol 98:1505—1513, 1984
56. SINaI! AK, SCHWARTZ MM: Nephntogenicity and immunocyto-
chemical localization of the 7OkD glycoprotein subunit (gp7O) of
Heymann antigen. C/in Immuno/ Immunopatho/ 48:61—77, 1988
57. KERJASCHKI D, HORVAT R, BINDERS, SUSANI M, DEKAN 0, OJHA
PP, HILLEMANS P, ULRICH W, DONNINI U: Identification of a
400-kd protein in the brush borders of human kidney tubules that is
similar to gp330, the nephritogenic antigen of rat heymann nephri-
tis. Am J Pathol 129:183—191, 1987
58. KERJASCHKI D: Molecular pathogenesis of membranous nephrop-
athy. Kidney Int 41:1090—1 105, 1992
59. ANDRES 0 BRENTJENS JR. CALDWELL PRB, CAMUSSI G, MATSUO
5: Biology of disease. Formation of immune deposits and disease.
Lab Invest 55:510—520, 1986
60. BRENTJENS JR, ANDRES GA: Interaction of antibodies with renal
surface antigens. Kidney Int 35:954—968, 1989
61. RODMAN JS, KERJASCHKI D, MERISKO E, FARQUHAR MG: Pres-
ence of an extensive clathrin coat on the apical plasmalemma of the
rat kidney proximal tubule cell. J Cell Blo/ 98:1630-1636, 1984
62. RODMAN JS, SEIDMAN L, FARQUHAR MG: The membrane compo-
sition of coated pits, microvilli, endosomes, and lysosomes is
distinctive in the rat kidney proximal tubule cell. J Cell Biol
102:77—87, 1986
63. DOXSEY S, KERJASCHKI D, FARQUHAR MG: A large membrane
glycoprotein (gp330) is a resident of coated pits of several absorp-
tive epithelia. (abstract) J Cell Biol 97: 178a, 1983
64. RAYCHOWDHURY R, NILES JL, MCCLUSKEY RT, SMITH JA Au-
toimmune target in Heymann nephritis is a glycoprotein with
homology to the LDL receptor. Science 244:1163—1165, 1989
65. PIETROM0NACO 5, KERJASCHKI D, BINDER S, ULLRICH R, FARQU-
HAR MG: Molecular cloning of a cDNA encoding a major patho-
genic domain of the heymann nephntis antigen gp330. Proc Nat!
AcadSci USA 87:1811—1815, 1990
66. SPECHT GRIJP-GLANDORF RJ, DE HEaR E, DEKKER-NOOREN CEM,
DAHA MR, VAN Es LA: Specificity and cross-reactive idiotypes of
anti-gp330 autoantibodies in active Heymann nephritis. Immuno/-
ogy 70:290—295, 1990
67. ALLEGRI L, BRIANTI E, CHATELET F, MANARA GC, RONCO P,
134 Yee and Neilson: Immune system mechanisms
VERROUST P: Polyvalent antigen-antibody interactions are required
for the formation of electron dense deposits in passive Heymann
nephritis. Am J Pathol 125:1—6, 1986
68. COUSER WG: Mediation of glomerular injury. J Am Soc Nephrol
1:13—29, 1990
69. COUSER WG, STILMANT MM, LEWIS EJ: Experimental glomeru-
lonephritis in the guinea pig. II. Ultrastructural lesions of the
basement membrane associated with proteinuria. Lab Invest 32:46—
55, 1975
70. FOGEL MA, BOYD CD, LEARDKAMOLKARN V, ABRAHAMSON DR,
MINT0 AWM, SALANT DJ: Glomerular basement membrane ex-
pansion in passive heymann nephritis: Absence of increased syn-
thesis of type IV collagen, laminin, or fibronectin. Am J Pathol
138:465—475, 1991
71. FUKATSU A, MATSUO S, KILLEN PD, MARTIN GR, ANDRES GA,
BRENTIENS JR: The glomerular distribution of type IV collagen and
laminin in human membranous glomerulonephritis. Hum Pathol
19:64—68, 1988
72. HANSCH GM, TORBOHM I, ROTHER K: Chronic glomerulonephritis:
Inflammatory mediators stimulate the collagen synthesis in glomer-
ular epithelial cells. Int Arch Allergy Appl Irnmunol 88:139—143,
1989
73. MATSUO S. BRENTJENS JR. ANDRES G, FOIDART JM, MARTIN GR,
MARTINEZ-HERNANDEZ A: Distribution of basement membrane
antigens in glomeruli of mice with autoimmune glomerulonephritis.
Am J Pathol 122:36—49, 1986
74. TORBOHM I, SCHOENERMARK M, WINGEN AM, BERGER B,
ROTHER K, HANSCH GM: C5b-8 and CSb-9 modulate the collagen
release of human glomerular epithelial cells. Kidney Int 37:1098—
1104, 1990
75. CAMUSSI 0, NOBLE B, VAN LIEw J, BRENTJENS JR. ANDRES G:
Pathogenesis of passive Heymann glomerulonephritis: Chlorprom-
azine inhibits antibody-mediated redistribution of cell surface anti-
gens and prevents development of the disease. J Immunol 136:
2127—2135, 1986
76. CYBULSKY AV, QUIQQ RJ, BADALAMENTI J, SALANT DJ: Anti-
Fxl-A induces association of heymann nephritis antigens with
microfflaments of cultured glomerular visceral epithelial cells. Am J
Pathol 129:373—384, 1987
77. GUTMANN EJ, NILES JL, MCCLUSKEY RT, BROWN D: Colchicine-
induced redistribution of an apical membrane glycoprotein (gp330)
in kidney tubules. Am J Physiol 257:C397—C407, 1989
78. MENDRICK DL, CHUNG DC, RENNKE HG: Heymann antigen gp330
demonstrates affinity for fibronectin, laminin, and type I collagen
and mediates adherence of rat proximal tubule epithelial cell
adherence to such matrices in vitro. Exp Cell Res 188:23—35, 1990
79. RUOSLAHTI E: Integrins. J Clin Invest 87:1—5, 1991
80. HYNES D: Integrins: A family of cell surface receptors. Cell
48:549—554, 1987
81. ABRAHAMSON DR, WooDs A, COUCHMAN JR, CHATHAM WW,
HECK LW: Cell surface receptors for kidney basement membranes.
AmJKidDis 12:78—83, 1988
82. GUTTMAN EJ, NILES JL, MCCLUSKEY RT: Loss of antigens
associated with the endocytic pathway in proximal tubules from
rats with heymann nephritis. Am J Pathol 138:1243—1255, 1991
83. ORIKASA M, MATSUI K. OITE T, SHIMIZU F: Massive proteinuria
induced in rats by a single intravenous injection of a monoclonal
antibody. J Immunol 141:807—814, 1988
84. BARNES JL, RADNIK RA, GILCHRIST EP, VENKATACHALAM MA:
Size and charge selective permeability defects induced in glomer-
ular basement membrane by a polycation. Kidney Int 25:11—19,
1984
85. WASHIZAWA K, ISHII K, ITOH N, Mom T, AKABANA T, SHIGE-
MATSU H: Morphometric changes in the glomerular anionic Sites
during aminonucleoside nephrosis. Acta Pathol 39:558—565, 1989
86. KANWAR YS, ROSENZWEIG U: Altered glomerular permeability as
a result of focal detachment of the visceral epithelium. Kidney Int
21 :565—574, 1982
87. MESSINA A, DAVIES DJ, DILLANE PC, RYAN GB: Gloerular
epithelial abnormalities associated with the onset of proteinuna in
aminonucleoside nephrosis. Am J Pathol 126:220—229, 1987
88. FISHMAN JA, KARNOVSKY MJ: Effects of the aminonucleoside of
puromycin on glomerular epithelial cells in vitro. Am J Pathol
118:398—407, 1985
89. CAULFIELD JP, FARQUIIAR MG: The permeability of glomerular
capillaries of aminonucleoside nephrotic rats to graded dextrans. J
Exp Med 142:61—83, 1975
90. WEENING JJ, VAN GULDENER C, DAHA MR, KLAR N, VAN DEN
WAL A, PRINS FA: The pathophysiology of protein-overload pro-
teinuria. Am J Pathol 129:64—73, 1987
91. BERTANI G, POGGI A, PozzoNi R, DELAINI F, SACCHI G, MECCA
G, REMUZZI G, DONATI MB: Adriamycin-induced nephrotic syn-
drome in rats: sequence of pathologic events. Lab Invest 46:16—23,
1982
92. MENDRICK DL, RENNKE HG: I. Induction of proteinuria in the rat
by a monoclonal antibody. Kidney mt 33:818—830, 1988
93. MENDRICK DL, RENNKE HG: II. Epitope specific induction of
proteinuria by monoclonal antibodies. Kidney mt 33:831—842, 1988
94. HAVERTY TP, WATANABE M, NEILSON EG, KELLY CJ: Protective
modulation of class H MHC gene expression in tubular epithelium
by target antigen-specific antibodies. Cell-surface directed down-
regulation of transcription can influence the susceptibility to murine
tubulointerstitial nephritis. J Immunol 143:1133—1141, 1989
95. JEVNIKAR AM, WUTHRICH RP, TAKEI F, Xu HW, BRENNAN DC,
GLIMCHER LH, KELLY YE: Differing regulation and function of
ICAM-l and class II antigens on renal tubular cells. Kidney mt
38:417—425, 1990
96, HINES WH, HAVERTY TP, ELIAS JA, NEILSON EG, KELLY CJ: T
cell recognition of epithelial self. Autoimmunity 5:37—47, 1989
97. WUTHRICH RP, GLIMCHER LH, Yui MA, JEVNIKAR AM, DUMAS
SE, KELLEY YE: Generation of highly differentiated murine renal
tubular epithelial cell lines: MHC class II regulation, antigen
presentation, and tumor necrosis factor production. Kidney Int
37:783—792, 1990
